medigraphic.com
ISSN 2007-3194 (Print)
Órgano de difusión oficial del Instituto Materno Infantil del Estado de México

2022, Number 1

<< Back Next >>

Arch Inv Mat Inf 2022; 13 (1)

Usefulness of oral tranexamic acid for the prevention of obstetric haemorrhage in women with term pregnancy

Barrios SAC, Castillejos LO

Language: Spanish
References: 29
Page: 5-12
PDF size: 237.90 Kb.


ABSTRACT

Introduction: obstetric hemorrhage is one of the main causes of maternal death in the world. The main study groups worldwide have recommended early identification of risk factors and active management of the third stage of labor to avoid it. Material and methods: observational-analytical and cross-sectional study; with a population of 100 female patients with risk factors for obstetric hemorrhage, divided into two groups: a study group who were administered 1,300 mg of oral tranexamic acid as a preventive method and a control group. The data is analyzed with normality tests and a p < 0.05 is considered as significant results. Results: the usefulness of orally administered tranexamic acid to prevent obstetric hemorrhage, with a reduction in the relative risk of hemorrhage, was 80% when it occurred in the control group. Conclusion: it was concluded that tranexamic acid is effective as a preventive method of obstetric hemorrhage, finding a lower incidence in the study group.


REFERENCES

  1. Diagnóstico y tratamiento del choque hemorrágico en obstetricia. Guía de Evidencias y Recomendaciones: Guía de Práctica Clínica. México. IMSS; 2017.

  2. Kruithof EK, Tran-Thang C, Gudinchet A, Hauert J, Nicoloso G, Genton C et al. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood. 1987; 69 (2): 460-466.

  3. Alves AL, Francisco AA, Osanan CC, Vleira LB. Postpartum hemorrhage: prevention, diagnosis and non-surgical management. Rev Bras Ginecol Obstet. 2020; 42 (11): 776-784. doi: 10.1055/s-0040-1721882.

  4. Muñoz M, Stensballe J, Ducloy-Bouthors AS, Bonnet MP, De Robertis E, Fornet I et al. Patient blood management in obstetrics: prevention and treatment of postpartum haemorrhage. A NATA consensus statement. Blood Transfus. 2019; 17 (2): 112-136. doi: 10.2450/2019.0245-18.

  5. Dubber AH, McNicol GP, Douglas AS. Amino-methyl-cyclohexane-carboxylic acid (AMCHA),. a new synthetic inhibitor. Br J Haematol. 1965; 11: 237-245.

  6. Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 183: Postpartum Hemorrhage. Obstet Gynecol. 2017; 130 (4): e168-e186.

  7. Bose P, Regan F, Paterson-Brown S. Improving the accuracy of estimated blood loss at obstetric haemorrhage using clinical reconstructions. BJOG. 2006; 113 (8): 919-924.

  8. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol. 2005; 129 (3): 307-221. doi: 10.1111/j.1365-2141.2005.05444.x

  9. Lucas MA, Fretto LJ, McKee PA. The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem. 1983; 258 (7): 4249-4256.

  10. Bonnar K, Davidson JF, Pidgeon CF, McNicol GP, Douglas AS. Fibrin degradation products in normal and abnormal pregnancy. Br Med J. 1969; 3 (5663): 137-140. doi: 10.1136/bmj.3.5663.137.

  11. Penguelly-Cruz CA, Cruz-Durán JG. Uso de gluconato de calcio como agente terapéutico contra atonía uterina en mujeres con factores de riesgo en el Hospital de Ginecoobstetricia 3 de La Raza. UNAM. IMSS. [Tesis]. 2014.

  12. Shakur H, Beaumont D, Payord S, Gayet-Ageron A, Ker K, Mousa HA. Antifibrinolytic drugs for treating primary postpartum haemorrhage. Cochrane Database Syst Rev. 2018; 2018 (2): CD012964. doi: 10.1002/14651858.CD012964.

  13. Vogel JP, Oladapo OT, Dowswell T, Gülmezoglu AM. Updated WHO recommendation on intravenous tranexamic acid for the treatment of post-partum haemorrhage. Lancet Glob Heal. 2018; 6 (1): e18-e19. doi: 10.1016/S2214-109X(17)30428-X

  14. Gayet-Ageron A, Prieto-Merino D, Ker K, Shakur H, Ageron FX, Roberts I. Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40,138 bleeding patients. Lancet. 2018; 391 (101): 125-132. doi: 10.1016/S0140-6736(17)32455-8.

  15. Shakur H, Fawole B, Kuti M, Olayemi OO, Bello A, Ogunbode O et al. Effect of tranexamic acid on coagulation and fibrinolysis in women with postpartum haemorrhage (WOMAN-ETAC): protocol and statistical analysis plan for a randomized controlled trial. [version 1; peer review: 3 approved]. Wellcome Open Res. 2016; 1: 31.

  16. Shakur H, Roberts I, Edwars P, Elbourne D, Alfirevic Z, Ronsmans C. The effect of tranexamic acid on the risk of death and hysterectomy in women with post-partum haemorrhage: statistical analysis plan for the WOMAN trial. Trials. 2016; 17: 249.

  17. Brenner A, Arribas M, Cuzick J, Jairath V, Stabwort S, Ker K et al. Outcome measures in clinical trials of treatments for acute severe haemorrhage. Trials. 2018; 19 (1): 533.

  18. WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017; 389 (10084): 2105-2116.

  19. WHO Recommendation on tranexamic acid for the treatment of postpartum haemorrhage. Geneva. World Health Organization 2017.

  20. Ker K, Shakur H, Roberts I. Does tranexamic acid prevent postpartum haemorrhage? A systematic review of randomised controlled trials. BJOG. 2016; 123 (1): 1745-1752.

  21. Brenner A, Shakur-Still H, Chaudhri R, Fawole B, Arulkumaran S, Roberts I. The impact of early outcome events on the effect of tranexamic acid in post-partum haemorrhage: an exploratory subgroup analysis of the WOMAN trial. BMC Pregnancy Childbirth. 2018; 18: 215.

  22. Sentilhes L, Winer N, Azria E, Sénat MV, Le Ray C, Vardon D et al. Tranexamic acid for the prevention of blood loss after vaginal delivery. N Engl J Med. 2018; 379: 731-742.

  23. Ducloy-Bouthors AS, Jude B, Duhamel A, Broisin F, Huissoud C, Keita-Meyer H et al. High-dose tranexamic acid reduces blood loss in postpartum haemorrhage. Crit Care. 2011; 15 (2): R117.

  24. Piamo-Morales AJ, Rojas MA. Uso de ácido tranexámico en las hemorragias. Rev Cubana Cir. 2018; 57 (4): 72-79.

  25. Tengborn L. Inhibidores fibrinolíticos en el control de trastornos de la coagulación. Tratamiento de la Hemofilia. FMH. Quebec, Canada. 2012; No. 42.

  26. Ker K. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ. 2012; 344: e3054.

  27. Meber S, Cuthbert A, Kirkham JJ, Williamson P, Abalos E, Aflaifel N et al. Core outcome sets for prevention and treatment of postpartum haemorrhage: an international Delphi consensus study. BJOG. 2019; 126 (1): 83-93.

  28. Parry SW, Gallos ID, Williams HM, Widmer M, Angolkar M, Tobias A et al. First-line uterotonics for treating postpartum haemorrhage: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2017; 2017 (8): CD012754.

  29. Nyflot LT, Sandven I, Stray-Pedersen B, Pettersen S, Al-Zirqi I, Rosenberg M et al. Risk factors for severe postpartum hemorrhage: a case-control study. BMC Pregnancy Childbirth. 2017; 17 (1): 17.




2020     |     www.medigraphic.com